As a specialized CDMO, we sit at the intersection of discovery vision and commercial reality, translating antibody concepts into manufacturable biotherapeutics. Our chimeric antibody program is an integral part of our core businesses – Pharmaceutical Development & Manufacturing, Drug Substance Development, and Monoclonal Antibody Development – ensuring seamless integration at every stage.
Overview of Chimeric Antibody Development
Chimeric antibodies fuse murine variable domains with human constant regions to balance high-affinity recognition with reduced immunogenicity. Development therefore demands disciplined molecular design, robust expression technologies, and phase-appropriate analytics. We coordinate these elements under one roof, beginning with sequence liability screening and extending through IND-ready cGMP drug substance. By aligning structural biology, cell-line engineering, bioprocess optimization, and regulatory CMC support early, we compress timelines, mitigate risk, and deliver reliable clinical supply without needless tech-transfers.
Our Services
We offer an end-to-end, fully integrated CDMO pathway that moves chimeric antibodies from sequence to stable, clinic-ready bulk under one roof. We begin with a predictive feasibility and project-design assessment that lays out a costed, risk-balanced development roadmap. Next, our proprietary platforms generate robust producer cell lines that feed seamlessly into scale-correlated upstream bioreactors. A streamlined three-column purification train—and, when needed, continuous-processing alternatives—delivers high purity and recovery, while formulation scientists fine-tune pH, excipients, and surfactants to lock in long-term stability.
Feasibility & Project Design Service
We begin every engagement with an in-silico manufacturability and liability assessment. Structure-based modeling flags potential deamidation sites, MHC-II epitopes, and glycosylation motifs that could complicate downstream processing. Parallel risk mapping and resource modeling generate a practical development plan with costed timelines, material demand forecasts, and built-in comparability triggers. Sponsors receive a data-rich report that underpins both scientific steering and financial decision-making.
Cell Line & Vector Engineering Service
Leveraging our proprietary platforms, we codon-optimize the chimeric heavy and light chains, assemble single-or dual-promoter vectors, and integrate them via targeted recombination or transposon-mediated systems. Stable pools are screened in high-throughput micro-bioreactors for titer, glycan uniformity, and charge heterogeneity. Top clones transfer into fed-batch shake-flasks for confirmation, after which we initiate full cell-banking under GMP, complete with genetic stability and viral safety testing.
Upstream Bioprocess Development Service
Process scientists apply design-of-experiment matrices to define critical parameters such as feed ratios, osmolality, and temperature-shift profiles. Small-scale models are rigorously correlated to our single-use bioreactors up to 2 000 L, ensuring predictable scale-up. We also establish platform media and high-productivity perfusion options for campaigns that demand rapid turnaround or large clinical volumes.
Downstream Purification & Formulation Service
Our three-column platform — protein A capture, low-pH viral inactivation, and mixed-mode polishing — consistently meets purity and recovery targets while preserving Fc receptor binding. Continuous-processing alternatives (multi-column chromatography, single-pass tangential flow) are available for programs prioritizing volume efficiency. Formulation scientists then screen pH, excipient, and surfactant spaces to stabilize the chimeric antibody for refrigerated or frozen storage, generating Drug formulation specification sheet (DFSS) and container-closure compatibility data packages.
From molecular blueprint to bulk, we orchestrate every facet of chimeric antibody development within an agile CDMO framework. Engage us to accelerate your program with confidence and scientific rigor.
Frequently Asked Questions
Q1: How early should we involve you in a chimeric project?
Engagement at the gene-sequence stage lets us identify manufacturability liabilities before they become costly, but we can seamlessly onboard programs at any downstream point, including post-cell-line construction.
Q2: Do you offer platform processes or bespoke development?
Our standard platforms cover the majority of chimeric IgG subclasses, delivering cost and schedule advantages. When a molecule falls outside platform space — for example, unusual isotypes or Fc-modified formats — we customize media, feed, or purification trains while preserving compliant documentation.
Our products and services are for research use only.
